Sanofi-Aventis Eyes Expanded Menactra Indication Following Initial Approval

FDA approves the meningococcal conjugate vaccine for patients 11-55 years old; Sanofi-Aventis will submit a sBLA for use in children ages 2-11 by February. The company is currently studying the vaccine in patients under age 2 and will initiate a study evaluating Menactra in subjects over age 55 years by January 2006.